世界の加齢黄斑変性症（AMD/ARMD）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Age-related Macular Degeneration Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0159 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、加齢黄斑変性症（AMD/ARMD）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ウェットAMD、ドライAMD）、用途別市場規模（ドラッグストア、病院、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・加齢黄斑変性症（AMD/ARMD）の市場動向 ・企業の競争状況、市場シェア ・加齢黄斑変性症（AMD/ARMD）の種類別市場規模（ウェットAMD、ドライAMD） ・加齢黄斑変性症（AMD/ARMD）の用途別市場規模（ドラッグストア、病院、その他） ・加齢黄斑変性症（AMD/ARMD）の北米市場規模2016-2027（アメリカ、カナダ） ・加齢黄斑変性症（AMD/ARMD）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・加齢黄斑変性症（AMD/ARMD）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・加齢黄斑変性症（AMD/ARMD）の中南米市場規模2016-2027（メキシコ、ブラジル） ・加齢黄斑変性症（AMD/ARMD）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bayer HealthCare、F. Hoffmann-La Roche、Novartis、Regeneron Pharmaceuticals、Alcon、Allergan、Avalanche、Bausch+Lomb、Gilead Sciences、Iconic Therapeutics、Neurotech Pharmaceuticals、Ohr Pharmaceutical） ・結論

Market Analysis and Insights: Global Age-related Macular Degeneration Market
The global Age-related Macular Degeneration market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Age-related Macular Degeneration market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Age-related Macular Degeneration market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Age-related Macular Degeneration market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Age-related Macular Degeneration market.

Global Age-related Macular Degeneration Scope and Market Size
Age-related Macular Degeneration market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Age-related Macular Degeneration market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Wet AMD
Dry AMD

Segment by Application
Drugstore
Hospital
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bayer HealthCare
F. Hoffmann-La Roche
Novartis
Regeneron Pharmaceuticals
Alcon
Allergan
Avalanche
Bausch+Lomb
Gilead Sciences
Regeneron Pharmaceuticals

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Age-related Macular Degeneration Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Wet AMD
1.2.3 Dry AMD
1.3 Market by Application
1.3.1 Global Age-related Macular Degeneration Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Drugstore
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Age-related Macular Degeneration Market Perspective (2016-2027)
2.2 Age-related Macular Degeneration Growth Trends by Regions
2.2.1 Age-related Macular Degeneration Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Age-related Macular Degeneration Historic Market Share by Regions (2016-2021)
2.2.3 Age-related Macular Degeneration Forecasted Market Size by Regions (2022-2027)
2.3 Age-related Macular Degeneration Industry Dynamic
2.3.1 Age-related Macular Degeneration Market Trends
2.3.2 Age-related Macular Degeneration Market Drivers
2.3.3 Age-related Macular Degeneration Market Challenges
2.3.4 Age-related Macular Degeneration Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Age-related Macular Degeneration Players by Revenue
3.1.1 Global Top Age-related Macular Degeneration Players by Revenue (2016-2021)
3.1.2 Global Age-related Macular Degeneration Revenue Market Share by Players (2016-2021)
3.2 Global Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Age-related Macular Degeneration Revenue
3.4 Global Age-related Macular Degeneration Market Concentration Ratio
3.4.1 Global Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Age-related Macular Degeneration Revenue in 2020
3.5 Age-related Macular Degeneration Key Players Head office and Area Served
3.6 Key Players Age-related Macular Degeneration Product Solution and Service
3.7 Date of Enter into Age-related Macular Degeneration Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Age-related Macular Degeneration Breakdown Data by Type
4.1 Global Age-related Macular Degeneration Historic Market Size by Type (2016-2021)
4.2 Global Age-related Macular Degeneration Forecasted Market Size by Type (2022-2027)

5 Age-related Macular Degeneration Breakdown Data by Application
5.1 Global Age-related Macular Degeneration Historic Market Size by Application (2016-2021)
5.2 Global Age-related Macular Degeneration Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Age-related Macular Degeneration Market Size (2016-2027)
6.2 North America Age-related Macular Degeneration Market Size by Type
6.2.1 North America Age-related Macular Degeneration Market Size by Type (2016-2021)
6.2.2 North America Age-related Macular Degeneration Market Size by Type (2022-2027)
6.2.3 North America Age-related Macular Degeneration Market Size by Type (2016-2027)
6.3 North America Age-related Macular Degeneration Market Size by Application
6.3.1 North America Age-related Macular Degeneration Market Size by Application (2016-2021)
6.3.2 North America Age-related Macular Degeneration Market Size by Application (2022-2027)
6.3.3 North America Age-related Macular Degeneration Market Size by Application (2016-2027)
6.4 North America Age-related Macular Degeneration Market Size by Country
6.4.1 North America Age-related Macular Degeneration Market Size by Country (2016-2021)
6.4.2 North America Age-related Macular Degeneration Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Age-related Macular Degeneration Market Size (2016-2027)
7.2 Europe Age-related Macular Degeneration Market Size by Type
7.2.1 Europe Age-related Macular Degeneration Market Size by Type (2016-2021)
7.2.2 Europe Age-related Macular Degeneration Market Size by Type (2022-2027)
7.2.3 Europe Age-related Macular Degeneration Market Size by Type (2016-2027)
7.3 Europe Age-related Macular Degeneration Market Size by Application
7.3.1 Europe Age-related Macular Degeneration Market Size by Application (2016-2021)
7.3.2 Europe Age-related Macular Degeneration Market Size by Application (2022-2027)
7.3.3 Europe Age-related Macular Degeneration Market Size by Application (2016-2027)
7.4 Europe Age-related Macular Degeneration Market Size by Country
7.4.1 Europe Age-related Macular Degeneration Market Size by Country (2016-2021)
7.4.2 Europe Age-related Macular Degeneration Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Age-related Macular Degeneration Market Size (2016-2027)
8.2 Asia-Pacific Age-related Macular Degeneration Market Size by Type
8.2.1 Asia-Pacific Age-related Macular Degeneration Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Age-related Macular Degeneration Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Age-related Macular Degeneration Market Size by Type (2016-2027)
8.3 Asia-Pacific Age-related Macular Degeneration Market Size by Application
8.3.1 Asia-Pacific Age-related Macular Degeneration Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Age-related Macular Degeneration Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Age-related Macular Degeneration Market Size by Application (2016-2027)
8.4 Asia-Pacific Age-related Macular Degeneration Market Size by Region
8.4.1 Asia-Pacific Age-related Macular Degeneration Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Age-related Macular Degeneration Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Age-related Macular Degeneration Market Size (2016-2027)
9.2 Latin America Age-related Macular Degeneration Market Size by Type
9.2.1 Latin America Age-related Macular Degeneration Market Size by Type (2016-2021)
9.2.2 Latin America Age-related Macular Degeneration Market Size by Type (2022-2027)
9.2.3 Latin America Age-related Macular Degeneration Market Size by Type (2016-2027)
9.3 Latin America Age-related Macular Degeneration Market Size by Application
9.3.1 Latin America Age-related Macular Degeneration Market Size by Application (2016-2021)
9.3.2 Latin America Age-related Macular Degeneration Market Size by Application (2022-2027)
9.3.3 Latin America Age-related Macular Degeneration Market Size by Application (2016-2027)
9.4 Latin America Age-related Macular Degeneration Market Size by Country
9.4.1 Latin America Age-related Macular Degeneration Market Size by Country (2016-2021)
9.4.2 Latin America Age-related Macular Degeneration Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Age-related Macular Degeneration Market Size (2016-2027)
10.2 Middle East & Africa Age-related Macular Degeneration Market Size by Type
10.2.1 Middle East & Africa Age-related Macular Degeneration Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Age-related Macular Degeneration Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Age-related Macular Degeneration Market Size by Type (2016-2027)
10.3 Middle East & Africa Age-related Macular Degeneration Market Size by Application
10.3.1 Middle East & Africa Age-related Macular Degeneration Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Age-related Macular Degeneration Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Age-related Macular Degeneration Market Size by Application (2016-2027)
10.4 Middle East & Africa Age-related Macular Degeneration Market Size by Country
10.4.1 Middle East & Africa Age-related Macular Degeneration Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Age-related Macular Degeneration Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bayer HealthCare
11.1.1 Bayer HealthCare Company Details
11.1.2 Bayer HealthCare Business Overview
11.1.3 Bayer HealthCare Age-related Macular Degeneration Introduction
11.1.4 Bayer HealthCare Revenue in Age-related Macular Degeneration Business (2016-2021)
11.1.5 Bayer HealthCare Recent Development
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Company Details
11.2.2 F. Hoffmann-La Roche Business Overview
11.2.3 F. Hoffmann-La Roche Age-related Macular Degeneration Introduction
11.2.4 F. Hoffmann-La Roche Revenue in Age-related Macular Degeneration Business (2016-2021)
11.2.5 F. Hoffmann-La Roche Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Age-related Macular Degeneration Introduction
11.3.4 Novartis Revenue in Age-related Macular Degeneration Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Regeneron Pharmaceuticals
11.4.1 Regeneron Pharmaceuticals Company Details
11.4.2 Regeneron Pharmaceuticals Business Overview
11.4.3 Regeneron Pharmaceuticals Age-related Macular Degeneration Introduction
11.4.4 Regeneron Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2016-2021)
11.4.5 Regeneron Pharmaceuticals Recent Development
11.5 Alcon
11.5.1 Alcon Company Details
11.5.2 Alcon Business Overview
11.5.3 Alcon Age-related Macular Degeneration Introduction
11.5.4 Alcon Revenue in Age-related Macular Degeneration Business (2016-2021)
11.5.5 Alcon Recent Development
11.6 Allergan
11.6.1 Allergan Company Details
11.6.2 Allergan Business Overview
11.6.3 Allergan Age-related Macular Degeneration Introduction
11.6.4 Allergan Revenue in Age-related Macular Degeneration Business (2016-2021)
11.6.5 Allergan Recent Development
11.7 Avalanche
11.7.1 Avalanche Company Details
11.7.2 Avalanche Business Overview
11.7.3 Avalanche Age-related Macular Degeneration Introduction
11.7.4 Avalanche Revenue in Age-related Macular Degeneration Business (2016-2021)
11.7.5 Avalanche Recent Development
11.8 Bausch+Lomb
11.8.1 Bausch+Lomb Company Details
11.8.2 Bausch+Lomb Business Overview
11.8.3 Bausch+Lomb Age-related Macular Degeneration Introduction
11.8.4 Bausch+Lomb Revenue in Age-related Macular Degeneration Business (2016-2021)
11.8.5 Bausch+Lomb Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Details
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Age-related Macular Degeneration Introduction
11.9.4 Gilead Sciences Revenue in Age-related Macular Degeneration Business (2016-2021)
11.9.5 Gilead Sciences Recent Development
11.10 Iconic Therapeutics
11.10.1 Iconic Therapeutics Company Details
11.10.2 Iconic Therapeutics Business Overview
11.10.3 Iconic Therapeutics Age-related Macular Degeneration Introduction
11.10.4 Iconic Therapeutics Revenue in Age-related Macular Degeneration Business (2016-2021)
11.10.5 Iconic Therapeutics Recent Development
11.11 Neurotech Pharmaceuticals
11.11.1 Neurotech Pharmaceuticals Company Details
11.11.2 Neurotech Pharmaceuticals Business Overview
11.11.3 Neurotech Pharmaceuticals Age-related Macular Degeneration Introduction
11.11.4 Neurotech Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2016-2021)
11.11.5 Neurotech Pharmaceuticals Recent Development
11.12 Ohr Pharmaceutical
11.12.1 Ohr Pharmaceutical Company Details
11.12.2 Ohr Pharmaceutical Business Overview
11.12.3 Ohr Pharmaceutical Age-related Macular Degeneration Introduction
11.12.4 Ohr Pharmaceutical Revenue in Age-related Macular Degeneration Business (2016-2021)
11.12.5 Ohr Pharmaceutical Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Wet AMD
Table 3. Key Players of Dry AMD
Table 4. Global Age-related Macular Degeneration Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Age-related Macular Degeneration Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Age-related Macular Degeneration Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Age-related Macular Degeneration Market Share by Regions (2016-2021)
Table 8. Global Age-related Macular Degeneration Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Age-related Macular Degeneration Market Share by Regions (2022-2027)
Table 10. Age-related Macular Degeneration Market Trends
Table 11. Age-related Macular Degeneration Market Drivers
Table 12. Age-related Macular Degeneration Market Challenges
Table 13. Age-related Macular Degeneration Market Restraints
Table 14. Global Age-related Macular Degeneration Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Age-related Macular Degeneration Market Share by Players (2016-2021)
Table 16. Global Top Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-related Macular Degeneration as of 2020)
Table 17. Ranking of Global Top Age-related Macular Degeneration Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Age-related Macular Degeneration Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Age-related Macular Degeneration Product Solution and Service
Table 21. Date of Enter into Age-related Macular Degeneration Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Age-related Macular Degeneration Revenue Market Share by Type (2016-2021)
Table 25. Global Age-related Macular Degeneration Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Age-related Macular Degeneration Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Age-related Macular Degeneration Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Age-related Macular Degeneration Revenue Market Share by Application (2016-2021)
Table 29. Global Age-related Macular Degeneration Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Age-related Macular Degeneration Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Age-related Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Age-related Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Age-related Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Age-related Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Age-related Macular Degeneration Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Age-related Macular Degeneration Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Age-related Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Age-related Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Age-related Macular Degeneration Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Age-related Macular Degeneration Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Age-related Macular Degeneration Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Age-related Macular Degeneration Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Age-related Macular Degeneration Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Age-related Macular Degeneration Market Size by Country (2022-2027) & (US$ Million)
Table 61. Bayer HealthCare Company Details
Table 62. Bayer HealthCare Business Overview
Table 63. Bayer HealthCare Age-related Macular Degeneration Product
Table 64. Bayer HealthCare Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 65. Bayer HealthCare Recent Development
Table 66. F. Hoffmann-La Roche Company Details
Table 67. F. Hoffmann-La Roche Business Overview
Table 68. F. Hoffmann-La Roche Age-related Macular Degeneration Product
Table 69. F. Hoffmann-La Roche Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 70. F. Hoffmann-La Roche Recent Development
Table 71. Novartis Company Details
Table 72. Novartis Business Overview
Table 73. Novartis Age-related Macular Degeneration Product
Table 74. Novartis Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. Regeneron Pharmaceuticals Company Details
Table 77. Regeneron Pharmaceuticals Business Overview
Table 78. Regeneron Pharmaceuticals Age-related Macular Degeneration Product
Table 79. Regeneron Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 80. Regeneron Pharmaceuticals Recent Development
Table 81. Alcon Company Details
Table 82. Alcon Business Overview
Table 83. Alcon Age-related Macular Degeneration Product
Table 84. Alcon Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 85. Alcon Recent Development
Table 86. Allergan Company Details
Table 87. Allergan Business Overview
Table 88. Allergan Age-related Macular Degeneration Product
Table 89. Allergan Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 90. Allergan Recent Development
Table 91. Avalanche Company Details
Table 92. Avalanche Business Overview
Table 93. Avalanche Age-related Macular Degeneration Product
Table 94. Avalanche Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 95. Avalanche Recent Development
Table 96. Bausch+Lomb Company Details
Table 97. Bausch+Lomb Business Overview
Table 98. Bausch+Lomb Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 99. Bausch+Lomb Recent Development
Table 100. Gilead Sciences Company Details
Table 101. Gilead Sciences Business Overview
Table 102. Gilead Sciences Age-related Macular Degeneration Product
Table 103. Gilead Sciences Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 104. Gilead Sciences Recent Development
Table 105. Iconic Therapeutics Company Details
Table 106. Iconic Therapeutics Business Overview
Table 107. Iconic Therapeutics Age-related Macular Degeneration Product
Table 108. Iconic Therapeutics Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 109. Iconic Therapeutics Recent Development
Table 110. Neurotech Pharmaceuticals Company Details
Table 111. Neurotech Pharmaceuticals Business Overview
Table 112. Neurotech Pharmaceuticals Age-related Macular Degeneration Product
Table 113. Neurotech Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 114. Neurotech Pharmaceuticals Recent Development
Table 115. Ohr Pharmaceutical Company Details
Table 116. Ohr Pharmaceutical Business Overview
Table 117. Ohr Pharmaceutical Age-related Macular Degeneration Product
Table 118. Ohr Pharmaceutical Revenue in Age-related Macular Degeneration Business (2016-2021) & (US$ Million)
Table 119. Ohr Pharmaceutical Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Age-related Macular Degeneration Market Share by Type: 2020 VS 2027
Figure 2. Wet AMD Features
Figure 3. Dry AMD Features
Figure 4. Global Age-related Macular Degeneration Market Share by Application: 2020 VS 2027
Figure 5. Drugstore Case Studies
Figure 6. Hospital Case Studies
Figure 7. Others Case Studies
Figure 8. Age-related Macular Degeneration Report Years Considered
Figure 9. Global Age-related Macular Degeneration Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Age-related Macular Degeneration Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Age-related Macular Degeneration Market Share by Regions: 2020 VS 2027
Figure 12. Global Age-related Macular Degeneration Market Share by Regions (2022-2027)
Figure 13. Global Age-related Macular Degeneration Market Share by Players in 2020
Figure 14. Global Top Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-related Macular Degeneration as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Age-related Macular Degeneration Revenue in 2020
Figure 16. Global Age-related Macular Degeneration Revenue Market Share by Type (2016-2021)
Figure 17. Global Age-related Macular Degeneration Revenue Market Share by Type (2022-2027)
Figure 18. North America Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 20. North America Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 21. North America Age-related Macular Degeneration Market Share by Country (2016-2027)
Figure 22. United States Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 26. Europe Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 27. Europe Age-related Macular Degeneration Market Share by Country (2016-2027)
Figure 28. Germany Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Age-related Macular Degeneration Market Share by Region (2016-2027)
Figure 38. China Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 46. Latin America Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 47. Latin America Age-related Macular Degeneration Market Share by Country (2016-2027)
Figure 48. Mexico Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Age-related Macular Degeneration Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Age-related Macular Degeneration Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Age-related Macular Degeneration Market Share by Country (2016-2027)
Figure 54. Turkey Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Age-related Macular Degeneration Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Bayer HealthCare Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 58. F. Hoffmann-La Roche Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 59. Novartis Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 60. Regeneron Pharmaceuticals Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 61. Alcon Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 62. Allergan Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 63. Avalanche Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 64. Bausch+Lomb Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 65. Gilead Sciences Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 66. Iconic Therapeutics Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 67. Neurotech Pharmaceuticals Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 68. Ohr Pharmaceutical Revenue Growth Rate in Age-related Macular Degeneration Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---